A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEVERWOUND Study)-Reference-Cited by-同舟云学术

A 3-month, Multicenter, Randomized, Open-label Study to Evaluate the Impact on Wound Healing of the Early (vs Delayed) Introduction of Everolimus in De Novo Kidney Transplant Recipients, With a Follow-up Evaluation at 12 Months After Transplant (NEVERWOUND Study)

Published:2020-02 Issue:2 Volume:104 Page:374-386
ISSN:0041-1337
Container-title:Transplantation
language:en
Short-container-title:

Author:

Manzia Tommaso Maria,Carmellini Mario,Todeschini Paola,Secchi Antonio,Sandrini Silvio,Minetti Enrico,Furian Lucrezia,Spagnoletti Gionata,Pisani Francesco,Piredda Gian Benedetto,Cappelli Gianni,Tisone GIuseppe

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Transplantation

Reference36 articles.

1. Everolimus in clinical practice--renal transplantation.;Pascual;Nephrol Dial Transplant,2006

2. Induction therapy and mTOR inhibition: minimizing calcineurin inhibitor exposure in de novo renal transplant patients.;Nashan;Clin Transplant,2013

3. Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from month 3: a multicentre, randomized trial.;Budde;Nephrol Dial Transplant,2017

4. Excellent long-term results in de novo renal transplant recipients treated with proliferation signal inhibitors and reduced calcineurin inhibitors exposure.;Carmellini;Transplant Proc,2008

5. Calcineurin inhibitors in renal transplantation still needed but in reduced doses: a review.;Ponticelli;Transplant Proc,2010

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunomodulators for Non-Melanoma Skin Cancers: Updated Perspectives;Clinical, Cosmetic and Investigational Dermatology;2023-04

2. Mammalian Target of Rapamycin Inhibitors and Wound Healing Complications in Kidney Transplantation: Old Myths and New Realities;Journal of Transplantation;2022-02-28

3. An overview of the efficacy and safety of everolimus in adult solid organ transplant recipients;Transplantation Reviews;2021-09

4. Wound healing adverse events in kidney transplant recipients receiving everolimus with reduced calcineurin inhibitor exposure or current standard-of-care: insights from the 24-month TRANSFORM study;Expert Opinion on Drug Safety;2020-07-20

5. Conversion to Everolimus was Beneficial and Safe for Fast and Slow Tacrolimus Metabolizers after Renal Transplantation;Journal of Clinical Medicine;2020-01-23